In mid-October 2023, Leica Microsystems, a microscopy and scientific instrumentation company from Germany, announced the opening of its new USD 60 million medical manufacturing and R&D facility in Singapore. One of the company’s four global production sites, its Singapore facility is expected to be solely responsible for the manufacturing of surgical microscopes for export to global markets, currently contributing to 40% of the company’s total revenue, as well as the manufacturing of microscopes for industrial applications. The new facility will house both product development and manufacturing departments, and is expected to double the company’s global production volume of surgical microscopes for international export.
The new, next-generation manufacturing facility is certified Green Mark Platinum, indicating that it has achieved the highest level of environmental performance, and is equipped with state-of-the-art digital technologies that enable a high level of automation, enhancing productivity. Additionally, Leica will be expanding its teams in research and development, regulatory affairs, quality assurance, and product management, growing the existing workforce to more than 500 people. The opening of its Singapore facility is expected to capitalize on the growing surgical microscope market, which is expected to grow by +14% (CAGR) over the next decade along with increasing demand for minimally invasive surgical procedures, such as brain, spinal cord or eye surgeries.
(Sources: Leica Microsystems)
